Literature DB >> 15956688

Receptors for relaxin family peptides.

Ross A Bathgate1, Richard Ivell, Barbara M Sanborn, O David Sherwood, Roger J Summers.   

Abstract

Recent studies have identified four receptors that are the physiological targets for relaxin family peptides. All are class I (rhodopsin like) G-protein-coupled receptors with LGR7 (RXFP1) and LGR8 (RXFP2) being type C leucine-rich repeat-containing receptors, whereas GPCR135 (RXFP3) and GPCR142 (RXFP4) resemble receptors that respond to small peptides such as somatostatin and angiotensin II. The cognate ligands for the receptors have been identified: relaxin for RXFP1; INSL3 for RXFP2; relaxin 3 for RXFP3 and INSL5 for RXFP4. RXFP1 and RXFP2 receptors produce increases in intracellular cAMP levels upon stimulation, although the response is complex and contains a component sensitive to PI-3-kinase inhibitors. There is also evidence that RXFP1 can activate Erk1/2 and nitric oxide synthase, and relaxin has been reported to enter cells and activate glucocorticoid receptors. In contrast, RXFP3 and RXFP4 couple to Gi by a pertussis toxin-sensitive mechanism to cause inhibition of cAMP production. Now that the receptors for relaxin family peptides and their cognate ligands have been identified, we suggest a nomenclature for both the peptides and the receptors that we hope will be helpful to researchers in this rapidly advancing field.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15956688     DOI: 10.1196/annals.1282.010

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  16 in total

1.  Relaxin-3/INSL7 regulates the stress-response system in the rat hypothalamus.

Authors:  Yoshihisa Watanabe; Yasumasa Miyamoto; Tomoyuki Matsuda; Masaki Tanaka
Journal:  J Mol Neurosci       Date:  2010-11-12       Impact factor: 3.444

Review 2.  The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease.

Authors:  Jennifer M Sasser
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-07-24       Impact factor: 3.619

Review 3.  Relevance of genetic investigation in male infertility.

Authors:  P Asero; A E Calogero; R A Condorelli; L Mongioi'; E Vicari; F Lanzafame; R Crisci; S La Vignera
Journal:  J Endocrinol Invest       Date:  2014-01-24       Impact factor: 4.256

4.  Primate preimplantation embryo is a target for relaxin during early pregnancy.

Authors:  Catherine A Vandevoort; Namdori R Mtango; Keith E Latham; Dennis R Stewart
Journal:  Fertil Steril       Date:  2011-06-08       Impact factor: 7.329

5.  Insulin signaling promotes germline proliferation in C. elegans.

Authors:  David Michaelson; Dorota Z Korta; Yossi Capua; E Jane Albert Hubbard
Journal:  Development       Date:  2010-02       Impact factor: 6.868

6.  Insulin-like 6 is induced by muscle injury and functions as a regenerative factor.

Authors:  Ling Zeng; Yuichi Akasaki; Kaori Sato; Noriyuki Ouchi; Yasuhiro Izumiya; Kenneth Walsh
Journal:  J Biol Chem       Date:  2010-08-31       Impact factor: 5.157

Review 7.  Impact of GPCRs in clinical medicine: monogenic diseases, genetic variants and drug targets.

Authors:  Paul A Insel; Chih-Min Tang; Ines Hahntow; Martin C Michel
Journal:  Biochim Biophys Acta       Date:  2006-10-05

8.  Relaxin induces matrix-metalloproteinases-9 and -13 via RXFP1: induction of MMP-9 involves the PI3K, ERK, Akt and PKC-ζ pathways.

Authors:  Nisar Ahmad; Wei Wang; Remi Nair; Sunil Kapila
Journal:  Mol Cell Endocrinol       Date:  2012-07-24       Impact factor: 4.102

9.  A novel role for relaxin-2 in the pathogenesis of primary varicosis.

Authors:  Julia Adams; Sarah Schott; Arno Bern; Matthias Renz; Kristian Ikenberg; Claus Garbe; Christian Busch
Journal:  PLoS One       Date:  2012-06-21       Impact factor: 3.240

10.  Structural basis of the aberrant receptor binding properties of hagfish and lamprey insulins.

Authors:  Waseem Sajid; Patricia A Holst; Vladislav V Kiselyov; Asser S Andersen; J Michael Conlon; Claus Kristensen; Thomas Kjeldsen; Jonathan Whittaker; Shu J Chan; Pierre De Meyts
Journal:  Biochemistry       Date:  2009-12-01       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.